


Stabilis



Piperacillin sodium / tazobactam



Noms commerciaux

Bagotaz	Argentine
Betampil	Equateur
Bioval	Chili
Petezam	Argentine
Piperac	Allemagne
Piperacillin tazobactam	Allemagne, Belgique, Canada
Piperazam	Brésil
Pipetazo	Chili
Pipitaz	Autriche
Pixamol	Colombie
Tazobac	Equateur, Italie, Portugal, Suisse
Tazocel	Espagne
Tazocilline	France
Tazocin	Afrique du sud, Argentine, Australie, Brésil, Colombie, Croatie, Danemark, Egypte, Emirats Arabes Unis, Finlande, Grande Bretagne, Grèce, Hongrie, Irlande du nord, Italie, Luxembourg, Mexique, Norvège, Nouvelle Zélande, Pays bas, Pérou, Pologne, Suède, Turquie
Tazonam	Autriche, Chili
Tazopip	Australie
Tazpen	Colombie, Mexique
Tazrobida	Colombie
Tigux	Chili
Tratac	Chili
Trital	Equateur
Zosyn	Etats Unis d'Amérique, Japon



Stabilité des solutions

		80 / 10 mg/ml	-15°C		30			274
		80 / 10 mg/ml	25°C		24			274
		80 / 10 mg/ml	4°C		7			274

		20 / 2.5 mg/ml	23°C		72				2345
		20 / 2.5 mg/ml	5°C		28				2345
		40 / 5 mg/ml	25°C		4				2026
		40 / 5 mg/ml	7°C		5				2026
		33.3 / 4.1 mg/ml	-20°C		90				1946
		33.3 / 4.1 mg/ml	4°C		35				1946
		80 / 10 mg/ml	23°C		72				2345
		80 / 10 mg/ml	5°C		28				2345
		40 / 5 mg/ml	25°C		3				2026
		40 / 5 mg/ml	7°C		17				2026
		50.6 / 6.3 mg/ml	2-8°C		17				4620
		50.6 / 6.3 mg/ml	25°C		3				4620
		33,3 / 4,1 mg/ml	-20°C		90				4148
		33,3 / 4,1 mg/ml	2-8°C		58				4148
		50.6 / 6.3 mg/ml	2-8°C		17				4621
		50.6 / 6.3 mg/ml	25°C		3				4621
		125/15,6 mg/ml	20-25°C		48				4634
		150 / 18,75 mg/ml	4°C		7				274
		150 / 18.75 mg/ml	-15°C		30				274
		150 / 18.75 mg/ml	25°C		24				274
		200 / 25 mg/ml	-15°C		30				274
		200 / 25 mg/ml	25°C		24				274
		200 / 25 mg/ml	4°C		7				274
		80 / 10 mg/ml	25°C		12				4326
		80 / 10 & 10 / 1.25 mg/ml	25°C		24				604
		80 / 10 & 10 / 1.25 mg/ml	4°C		7				604
		66,7/8,3 mg/ml	37°C		8				4634
		66,7/8,3 mg/ml	37°C		24				4634
		22 / 3 mg/ml	2-8°C		13				4512
		22 / 3 mg/ml	32°C		24				4512
		80 / 10 mg/ml	2-8°C		13				4512
		80 / 10 mg/ml	32°C		24				4512
		22 / 3 mg/ml	2-8°C		13				4512

		22 / 3 mg/ml	32°C		24			4512
		80 / 10 mg/ml	2-8°C		13			4512
		80 / 10 mg/ml	32°C		24			4512
		128 / 16 mg/ml	25°C		72			2042
		128 / 16 mg/ml	37°C		24			2042
		40 / 5 mg/ml	22-23°C		24			4758
		0.2 / 0.025 mg/ml	23°C		7			2451
		0.2 / 0.025 mg/ml	37°C		24			2451
		0.2 / 0.025 mg/ml	4°C		14			2451
		0.2 / 0.025 mg/ml	23°C		7			2451
		0.2 / 0.025 mg/ml	37°C		24			2451
		0.2 / 0.025 mg/ml	4°C		14			2451



Stabilité en mélange

		80/10 mg/ml	23°C		Ranitidine hydrochloride : 0,5 & 2 mg/ml	4		235
		20/2,5 >> 40/5 mg/ml	23°C		Ondansetron hydrochloride : 0,015 >> 0,15 mg/ml	4		16
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PVC		0,5/0,0625 mg/ml	37°C		Heparin sodium : 0,5 UI/ml	10		4180
PVC		0,5/0,0625 mg/ml	4°C		Heparin sodium : 0,5 UI/ml	168		4180
PP		20 / 2.5 mg/ml	22-23°C		Norepinephrine bitartrate : 0,032 mg/ml	24		4758



Facteur influençant la stabilité

				3586
--	--	--	--	------



Compatibilités

		Piperacillin sodium / tazobactam : 40/5 mg/ml Aciclovir sodium : 7 mg/ml		81
		Piperacillin sodium / tazobactam Amikacin sulfate		3586
		Piperacillin sodium / tazobactam : 40/5 mg/ml Aminophylline : 2.5 mg/ml		81
		Piperacillin sodium / tazobactam : 60 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Piperacillin sodium / tazobactam : 40/5 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Piperacillin sodium / tazobactam : 40/5 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Piperacillin sodium / tazobactam : 112.5 mg/ml Azithromycine : 2 mg/ml		1800
		Piperacillin sodium / tazobactam	RL	3586
		Piperacillin sodium / tazobactam Amikacin sulfate		3549
		Piperacillin sodium / tazobactam : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Piperacillin sodium / tazobactam : 200 mg/ml	RL	4603
		Piperacillin sodium / tazobactam Aciclovir sodium		3595
		Piperacillin sodium / tazobactam : 40/5 mg/ml Amphotericin B : 0.6 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Aztreonam : 40 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Bivalirudin : 5 mg/ml		1713
		Piperacillin sodium / tazobactam : 40/5 mg/ml Bleomycin sulfate : 1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Bumetanide : 0.04 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Buprenorphine hydrochloride : 0.04 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Butorphanol tartrate : 0.04 mg/ml		81
		Piperacillin sodium / tazobactam : 200 mg/ml Caffeine : 10 mg/ml		3964

		Piperacillin sodium / tazobactam : 40/5 mg/ml Calcium gluconate : 40 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Carboplatin : 5 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Carmustine : 1.5 mg/ml		81
		Piperacillin sodium / tazobactam : 90 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Piperacillin sodium / tazobactam : 40/5 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Piperacillin sodium / tazobactam : 40/5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Piperacillin sodium / tazobactam : 40/5 mg/ml Chlorpromazine hydrochloride : 2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Cimetidine hydrochloride : 12 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml		1415
		Piperacillin sodium / tazobactam Ciprofloxacin lactate		3529
		Piperacillin sodium / tazobactam : 80 mg/ml		3948
		Piperacillin sodium / tazobactam : 40/5 mg/ml Cisatracurium besylate : 0.1 & 2 mg/ml		299
		Piperacillin sodium / tazobactam : 40/5 mg/ml Cisatracurium besylate : 5 mg/ml		299
		Piperacillin sodium / tazobactam : 40/5 mg/ml Cisplatin : 1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Clindamycin phosphate : 10 mg/ml		81
		Piperacillin sodium / tazobactam : 225 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Piperacillin sodium / tazobactam : 40/5 mg/ml Co-trimoxazole : 0.8/4 mg/ml		81
		Piperacillin sodium / tazobactam : 40/0.5 mg/ml Colistin mesilate sodium : 1.5 mg/ml		3997
		Piperacillin sodium / tazobactam : 40/5 mg/ml Cyclophosphamide : 10 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Cytarabine : 50 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Dacarbazine : 4 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Daunorubicin hydrochloride : 1 mg/ml		81
		Piperacillin sodium / tazobactam Daunorubicin/cytarabine liposomale		4354
		Piperacillin sodium / tazobactam Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Piperacillin sodium / tazobactam : 40/5 mg/ml Dexamethasone sodium phosphate : 1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Piperacillin sodium / tazobactam Dimenhydrinate		2087











		Piperacillin sodium / tazobactam : 40/5 mg/ml Diphenhydramine hydrochloride : 2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Dobutamine hydrochloride : 4 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Docetaxel : 0.9 mg/ml		1754
		Piperacillin sodium / tazobactam : 40/5 mg/ml Dopamine hydrochloride : 3.2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Doxorubicin hydrochloride : 2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Piperacillin sodium / tazobactam : 40/5 mg/ml Doxycycline hyclate : 1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Droperidol : 0.4 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Enalaprilate : 0.1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Eravacycline : 0,6 mg/ml		4434
		Piperacillin sodium / tazobactam Erythromycin lactobionate		3674
		Piperacillin sodium / tazobactam : 40/5 mg/ml Etoposide : 0.4 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Piperacillin sodium / tazobactam : 40/5 mg/ml Famotidine : 2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Piperacillin sodium / tazobactam : 40/5 mg/ml Floxadine : 3 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Fluconazole : 2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Fludarabine phosphate : 1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Fluorouracil : 16 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Folate calcium : 2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Fosfomicin : 30 mg/ml		4055
		Piperacillin sodium / tazobactam : 40/5 mg/ml Furosemide : 3 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Gallium nitrate : 0.4 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Ganciclovir sodium : 20 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Piperacillin sodium / tazobactam Gentamicin sulfate		3520

		Piperacillin sodium / tazobactam Gentamicin sulfate		3643
		Piperacillin sodium / tazobactam Gentamicin sulfate		3586
		Piperacillin sodium / tazobactam : 40/5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Piperacillin sodium / tazobactam : 40/5 mg/ml Haloperidol lactate : 0.2 mg/ml		81
		Piperacillin sodium / tazobactam : 0.5/0.0625 mg/ml Heparin sodium : 0.5 UI/ml		4180
		Piperacillin sodium / tazobactam : 1.38/0.1725 mg/ml Heparin sodium : 1.4 UI/ml		4180
		Piperacillin sodium / tazobactam : 1.38/0.1725 mg/ml Heparin sodium : 1.4 UI/ml		4180
		Piperacillin sodium / tazobactam : 1.38/0.1725 mg/ml Heparin sodium : 1.4 UI/ml		4180
		Piperacillin sodium / tazobactam : 0.5/0.0625 mg/ml Heparin sodium : 0.5 UI/ml		4180
		Piperacillin sodium / tazobactam : 40/5 mg/ml Heparin sodium : 100 UI/ml		81
		Piperacillin sodium / tazobactam : 0.5/0.0625 mg/ml Heparin sodium : 0.5 UI/ml		4180
		Piperacillin sodium / tazobactam : 0.5/0.0625 mg/ml Heparin sodium : 0.5 UI/ml		4180
		Piperacillin sodium / tazobactam : 40/5 mg/ml Hetastarch : 60 mg/ml		1721
		Piperacillin sodium / tazobactam : 40/5 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Hydroxyzine dihydrochloride : 4 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Idarubicin hydrochloride : 0.5 mg/ml		81
		Piperacillin sodium / tazobactam		3586
		Piperacillin sodium / tazobactam : 40/5 mg/ml Ifosfamide : 25 mg/ml		81
		Piperacillin sodium / tazobactam : 166/20.83 mg/ml Insulin : 1 UI/ml		4254
		Piperacillin sodium / tazobactam : 45 mg/ml Insulin aspart : 1 UI/ml		1508
		Piperacillin sodium / tazobactam : 40/5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Piperacillin sodium / tazobactam : 40/5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Piperacillin sodium / tazobactam Kanamycin sulfate		3586
		Piperacillin sodium / tazobactam : 200 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Piperacillin sodium / tazobactam : 40/5 mg/ml Lansoprazole : 0.55 mg/ml		1625

		Piperacillin sodium / tazobactam : 166/20.83 mg/ml Levetiracetam : 20.83 mg/ml		4254
		Piperacillin sodium / tazobactam : 33,75 mg/ml Levetiracetam : 5 mg/ml		4569
		Piperacillin sodium / tazobactam : 45 mg/ml Levetiracetam : 5 mg/ml		4569
		Piperacillin sodium / tazobactam : 40/5 mg/ml Linezolid : 2 mg/ml		1925
		Piperacillin sodium / tazobactam : 40/5 mg/ml Lorazepam : 0.1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Magnesium sulfate : 100 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Mannitol : 150 mg/ml		81
		Piperacillin sodium / tazobactam : 200 mg/ml Meropenem : 50 mg/ml		4319
		Piperacillin sodium / tazobactam : 40/5 mg/ml Mesna : 10 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Methotrexate sodium : 15 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Methylprednisolone sodium succinate : 5 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Metoclopramide hydrochloride : 5 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Metronidazole : 5 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Minocycline hydrochloride : 1 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Mitomycin : 0.5 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Mitoxantrone dihydrochloride : 0.5 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Morphine sulfate : 1 mg/ml		81
		Piperacillin sodium / tazobactam N-acetylcysteine : 200 mg/ml		3766
		Piperacillin sodium / tazobactam : 40/5 mg/ml		301
		Piperacillin sodium / tazobactam : 40/5 mg/ml Nalbuphine hydrochloride : 10 mg/ml		81
		Piperacillin sodium / tazobactam : 200 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Piperacillin sodium / tazobactam Netilmicin sulfate		3586
		Piperacillin sodium / tazobactam : 20/2,5 & 40/5 mg/ml Ondansetron hydrochloride : 0,015 >> 0,15 mg/ml		16
		Piperacillin sodium / tazobactam : 40/5 mg/ml Ondansetron hydrochloride : 0.1 mg/ml		81
		Piperacillin sodium / tazobactam Pantoprazole sodium		2090
		Piperacillin sodium / tazobactam : 100 mg/ml Paracetamol : 10 mg/ml		4742

		Piperacillin sodium / tazobactam : 100 mg/ml Paracetamol : 10 mg/ml		3571
		Piperacillin sodium / tazobactam : 40/5 mg/ml Pethidine hydrochloride : 4 mg/ml		81
		Piperacillin sodium / tazobactam : 80 mg/ml		3948
		Piperacillin sodium / tazobactam : 200 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Piperacillin sodium / tazobactam Plazomicin sulfate		3586
		Piperacillin sodium / tazobactam : 40/5 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Piperacillin sodium / tazobactam : 160 mg/ml Posaconazole : 1,2 mg/ml		4521
		Piperacillin sodium / tazobactam : 40/5 mg/ml Potassium chloride : 100 mEq/l		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Prochlorperazine edysilate : 0.5 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Promethazine hydrochloride : 2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Ranitidine hydrochloride : 2 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Piperacillin sodium / tazobactam : 200 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Piperacillin sodium / tazobactam : 40/5 mg/ml Sargramostim : 10 µg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Sodium bicarbonate : 84 mg/ml		81
		Piperacillin sodium / tazobactam Sodium bicarbonate		3586
		Piperacillin sodium / tazobactam Streptomycin sulfate		3586
		Piperacillin sodium / tazobactam : 40/5 mg/ml Streptozocin : 40 mg/ml		81
		Piperacillin sodium / tazobactam : 40/5 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Piperacillin sodium / tazobactam : 40/5 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Piperacillin sodium / tazobactam : 40/5 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Piperacillin sodium / tazobactam : 40/5 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Piperacillin sodium / tazobactam Temocilline		4470
		Piperacillin sodium / tazobactam : 200 mg/ml Temocilline : 83.33 mg/ml		2231
		Piperacillin sodium / tazobactam : 166/20.83 mg/ml Thiamine hydrochloride : 0.4 mg/ml		4254
		Piperacillin sodium / tazobactam : 200 mg/ml Thiopental sodium : 25 mg/ml		3767

		Piperacillin sodium / tazobactam : 40/5 mg/ml Thiotepa : 1 mg/ml		81
		Piperacillin sodium / tazobactam Tigecycline		3332
		Piperacillin sodium / tazobactam Tobramycin sulfate		3586
		Piperacillin sodium / tazobactam : 1/0.125 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Piperacillin sodium / tazobactam : 200 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Piperacillin sodium / tazobactam : 10/1.25 >> 200/25 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Piperacillin sodium / tazobactam : 1/0.125 >> 200/25 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674
		Piperacillin sodium / tazobactam : 80 & 90 mg/ml Vancomycin hydrochloride : 8 mg/ml		3841
		Piperacillin sodium / tazobactam : 100/12,5 mg/ml Vancomycin hydrochloride : 10 mg/ml		3365
		Piperacillin sodium / tazobactam : 40 >> 100 mg/ml Vancomycin hydrochloride : 10 mg/ml		2475
		Piperacillin sodium / tazobactam Vancomycin hydrochloride : >8 mg/ml		3841
		Piperacillin sodium / tazobactam : 16 >> 100 mg/ml Vancomycin hydrochloride : 2 mg/ml		2475
		Piperacillin sodium / tazobactam : 16 >> 100 mg/ml Vancomycin hydrochloride : 5 mg/ml		2475
		Piperacillin sodium / tazobactam : 16 >> 30 mg/ml Vancomycin hydrochloride : 10 mg/ml		2475
		Piperacillin sodium / tazobactam : 30/3,75 mg/ml Vancomycin hydrochloride : 4 mg/ml		3421
		Piperacillin sodium / tazobactam : 40/5 mg/ml Vancomycin hydrochloride : 4 mg/ml		3421
		Piperacillin sodium / tazobactam : 33.75 >> 90 mg/ml Vancomycin hydrochloride : 4 >> 7 mg/ml		3841
		Piperacillin sodium / tazobactam : 33.75 >> 67.5 mg/ml Vancomycin hydrochloride : 8 mg/ml		3841
		Piperacillin sodium / tazobactam : 40/5 mg/ml Vancomycin hydrochloride : 10 mg/ml		81
		Piperacillin sodium / tazobactam : 112,5 mg/ml Vancomycin hydrochloride : 10 mg/ml		3428
		Piperacillin sodium / tazobactam : 80 >> 100 mg/ml Vancomycin hydrochloride : 4 mg/ml		2475
		Piperacillin sodium / tazobactam : 16 >> 100 mg/ml Vancomycin hydrochloride : 8 mg/ml		2475
		Piperacillin sodium / tazobactam : 28 mg/ml Vancomycin hydrochloride : 10 & 15 mg/ml		3984
		Piperacillin sodium / tazobactam : 67,5 mg/ml Vancomycin hydrochloride : 5 mg/ml		3960
		Piperacillin sodium / tazobactam : 16 >> 40 mg/ml Vancomycin hydrochloride : 4 mg/ml		2475
		Piperacillin sodium / tazobactam : 28 mg/ml Vancomycin hydrochloride : 5 mg/ml		3984

	Piperacillin sodium / tazobactam : 112.5 mg/ml Vasopressin : 0.2 UI/ml		2017
	Piperacillin sodium / tazobactam : 40/5 mg/ml Vinblastine sulfate : 0.12 mg/ml		81
	Piperacillin sodium / tazobactam : 40/5 mg/ml Vincristine sulfate : 0.05 mg/ml		81
	Piperacillin sodium / tazobactam : 40/5 mg/ml Zidovudine : 4 mg/ml		81
	Piperacillin sodium / tazobactam : 40/5 mg/ml		4655



Voie d'administration



Bibliographie

	Type	Source
16	Revue	Chung KC, Moon YSK, Chin A, Ulrich WU, Gill MA. Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1554-1556.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
235	Revue	Choi JS, Burm JP, Jhee SS, Chin A, Ulrich RW, Gill MA. Stability of piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium chloride injection during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 2273-2276.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
274	Revue	Moon YSK, Chung KC, Chin A, Gill MA. Stability of piperacillin sodium-tazobactam sodium in polypropylene syringes and polyvinyl chloride minibags. Am J Health-Syst Pharm 1995 ; 52: 999-1001.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.

604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1674	Revue	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.

1946	Revue	Hecq JD, Berlage V, Vanbeckbergen D, Jamart J, Galanti L. Effects of freezing, long-term storage, and microwave thawing on the stability of piperacillin plus tazobactam in 5% dextrose for infusion. Can J Hosp Pharm 2004 ; 57, 5: 276-282.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2026	Revue	Rigge D, Jones MF. Shelf lives of aseptically prepared medicines - stability of piperacillin/tazobactam in PVC and non-PVC bags. J Pharm Biomed Anal 2005 ; 39: 339-343.
2042	Revue	Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal β -lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2345	Revue	Donnelly R.F. Stability of aseptically prepared Tazocin solutions in polyvinyl chloride bags. Can J Hosp Pharm 2009 ; 62, 3: 226-231.
2451	Revue	Park TW, Le-Bui LP, Chung KC, Rho JP, Gill MA. Stability of piperacillin sodium-tazobactam sodium in peritoneal dialysis solutions Am J Health-Syst Pharm 1995 ; 52: 2022 - 2024.
2475	Revue	Wade J, Cooper M, Ragan R. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam Hosp Pharm 2015 ; 50: 376-379.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18

3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3365	Revue	Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A. Y-Site Compatibility of Vancomycin and Piperacillin/Tazobactam at Commonly Utilized Pediatric Concentrations. Hosp Pharm 2013 ; 1: 44-47
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3421	Revue	Leung E, Venkatesan N, Ly S.C, Scheetz M.H. Physical compatibility of vancomycin and piperacillin sodium–tazobactam at concentrations typically used during prolonged infusions. Am J Health-Syst Pharm 2013 ;70:1163-1166.
3428	Revue	Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A. Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations. Hosp Pharm 2013 ; 48, 1: 44-47.
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3529	Laboratoire	Ciprofloxacin – Summary of Product Characteristics Hospira 2013
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3586	Laboratoire	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3595	Laboratoire	Aciclovir - Summary of Product Characteristics Hospira 2009
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015










































3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3841	Revue	Nicholas O'Donnell J, Venkatesan N, Manek M, Rhodes N.J, Scheetz M.H. Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations. Am J Health-Syst Pharm 2016 ; 73:241-246
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
3960	Revue	Kufel W.D, Miller C.D, Johnson P.R, Reid K., Zahra J.J, Seabury R.W. Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story? Hosp Pharm 2017 ;52,2:132-137.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3984	Revue	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
3997	Revue	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4148	Revue	Huvelle S, Godet M, Galanti L, Closset M, Bihin B, Jamart J, Hecq J.D. Long-Term Stability Comparison between an Original and a Generic Version of Piperacillin/Tazobactam in Dextrose 5% Infusion Polyolefin Bags at 5+/-3°C after Microwave Freeze-Thaw Treatment. Pharmaceutical Technology in Hospital Pharmacy 2018
4180	Revue	Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R. Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions. Perit Dial Int 2018 ;38,6:430-440
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Revue	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4326	Revue	Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P. Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. Pharmazie 2019 ; 74: 357-362.














4354	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables. GERPAC Congress 2019 2019
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4470	Revue	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4512	Revue	Jamieson C,Ozolina L,Seaton RA, Gilchrist M, Hills T, Drummond F, Wilkinson AS. Assessment of the stability of citrate- buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements EJHP 2020 2020;0:1-5.
4521	Revue	Polo C, D'Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4538	Revue	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4569	Revue	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4620	Laboratoire de contrôle qualité	SimmsD, Roberts J, Rigge D. Stability Study for Piperacillin/Tazobactam 56.9 mg/mL in Sodium Chloride 0.9% w/v in 50mL Infusion Bags. Quality Control North West, Stockport NHS Foundati 2021
4621	Laboratoire de contrôle qualité	Simms D, Roberts J, Rigge D. Stability Study for Piperacillin/Tazobactam 56.9 mg/mL in Glucose 5.0% w/v in 50mL Infusion Bags. Quality Control North West, Stockport NHS Foundati 2021
4634	Revue	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4655	Revue	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4758	Revue	Schmidt J.P, Steppe M. Stability Study and Simultaneous Determination of Norepinephrine, Moxifloxacin, and Piperacillin + Tazobactam Mixtures Applied in Intensive Care Medicine . Curr Pharm Anal 2023 ; 19, 4: 307-316.

4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
------	-------	--



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Jour	 Non précisée
 Heure	 Chlorure de sodium 0,9%
 Lumière	 Glucose 5%
 Polyolefine	 Seringue polypropylène
 Elastomère en polyisoprène	 NaCl 0.9% tampon citrate 0.3% pH7
 Elastomère en silicone	 □ Elastomère (non précisé)
 Eau pour préparation injectable	 Non précisé
 Dianéal® PD2 4.25% glucose (Baxter)	 Dianéal® PD2 1.5% glucose (Baxter)
 Stabilité en mélange	 Solvant
 Molécule	 Verre
 Dianéal® PD1 1.5% glucose (Baxter)	 Dianéal® PD2 2.5% glucose (Baxter)
 Extraneal® (Baxter)	 Physionéal® 1.36 (Baxter)
 Physionéal® 2.27 (Baxter)	 Physionéal® 3.86 (Baxter)
 Polypropylène	 Facteur influençant la stabilité
 NaHCO ₃	 Provoque
 Dégradation	 Compatibilités
 Précipitation en 1 heure	 Incompatible
 Instabilité chimique	 Compatible
 Turbidité à 24 heures	 Précipitation immédiate
 Incompatibilité non précisée	RL Ringer lactate
 Aucun	 Turbidité immédiate
 Nutrition parentérale (mélange ternaire)	 Précipitation en 4 heures

	Incompatibilité subvisuelle		Perte de turbidité
	Dianéal® 4.25% glucose (Baxter)		Dianéal® 1.5% glucose (Baxter)
	Dianéal® 2.5% glucose (Baxter)		Solvant spécifique
	Changement de couleur à 4 heures		Nutrition parentérale (mélange binaire)
	Normosol®		Voie d'administration
	Perfusion intraveineuse		Bibliographie
	Dictionnaire		